Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Cancellation
---
identifier: "/us/fr/02-5043"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Cancellation"
title_number: 0
title_name: "Federal Register"
section_number: "02-5043"
section_name: "Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Cancellation"
positive_law: false
currency: "2002-03-01"
last_updated: "2002-03-01"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "02-5043"
document_type: "notice"
publication_date: "2002-03-01"
agencies:
- "Health and Human Services Department"
- "Food and Drug Administration"
fr_citation: "67 FR 9457"
fr_volume: 67
fr_action: "Notice."
---
# Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Cancellation
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice.
**SUMMARY:**
The Food and Drug Administration (FDA) is canceling the meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee scheduled for March 12, 2002. The meeting was announced in the *Federal Register* of February 7, 2002 (67 FR 5831).
**FOR FURTHER INFORMATION CONTACT:**
Thomas H. Perez, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-6758, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12542.
Dated: February 26, 2002.
Linda A. Suydam,
Senior Associate Commissioner for Communications and Constituent Relations.